TipRanks
Advertisement
Advertisement

ARMP Stock Latest News

Armata secures new U.S. funding for AP-SA02 Phase 3
Company AnnouncementsArmata secures new U.S. funding for AP-SA02 Phase 3
11d ago
8K
ARMP
Armata Pharmaceuticals receives $3.7M in additional funding from DoW
PremiumThe Fly
Armata Pharmaceuticals receives $3.7M in additional funding from DoW
11d ago
ARMP
Armata wins FDA Breakthrough Therapy for AP-SA02
PremiumCompany Announcements
Armata wins FDA Breakthrough Therapy for AP-SA02
20d ago
8K
ARMP
Armata Pharmaceuticals receives FDA Breakthrough Therapy Designation for AP-SA02
PremiumThe Fly
Armata Pharmaceuticals receives FDA Breakthrough Therapy Designation for AP-SA02
20d ago
ARMP
Armata Pharmaceuticals announces new published paper on Ar-KM
PremiumThe Fly
Armata Pharmaceuticals announces new published paper on Ar-KM
1M ago
ARMP
Analyst Maintains Buy on Armata as AP-SA02 Nears Phase 3, Backed by Regulatory Tailwinds and $20 DCF-Based Price Target
PremiumRatingsAnalyst Maintains Buy on Armata as AP-SA02 Nears Phase 3, Backed by Regulatory Tailwinds and $20 DCF-Based Price Target
1M ago
ARMP
Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained
Premium
Ratings
Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained
2M ago
ARMP
Armata Pharmaceuticals Promotes David House to CFO
Premium
Company Announcements
Armata Pharmaceuticals Promotes David House to CFO
3M ago
8K
ARMP
Armata Advances AP-SA02 Toward Phase 3 Trial Launch
PremiumCompany Announcements
Armata Advances AP-SA02 Toward Phase 3 Trial Launch
3M ago
8K
ARMP
Armata provides update on AP-SA02 studies
PremiumThe Fly
Armata provides update on AP-SA02 studies
3M ago
ARMP
Armata promotes David House to CFO
PremiumThe Fly
Armata promotes David House to CFO
3M ago
ARMP
FDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)
PremiumRatings
FDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)
3M ago
ARMP
Armata Advances AP-SA02 Pediatric Plan With FDA Agreement
PremiumCompany AnnouncementsArmata Advances AP-SA02 Pediatric Plan With FDA Agreement
3M ago
8K
ARMP
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
Premium
The Fly
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
3M ago
ARMP
Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding
Premium
The Fly
Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding
3M ago
ARMP
Armata gains new DoD funding for AP-SA02 advancement
PremiumCompany Announcements
Armata gains new DoD funding for AP-SA02 advancement
3M ago
8K
ARMP
Armata Shareholders Approve Directors, Executive Pay and Auditor
PremiumCompany Announcements
Armata Shareholders Approve Directors, Executive Pay and Auditor
4M ago
8K
ARMP
Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial
PremiumRatings
Analyst Reiterates Buy on Armata, Maintaining $20 Price Target Ahead of Pivotal Phase 3 AP-SA02 Trial
4M ago
ARMP
Armata Secures New Loan Amid Wider Quarterly Loss
PremiumCompany Announcements
Armata Secures New Loan Amid Wider Quarterly Loss
5M ago
8K
ARMP
Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
PremiumThe FlyArmata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
5M ago
ARMP
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
Premium
The Fly
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
5M ago
ARMP
Armata Gains FDA Fast Track for AP-SA02 Therapy
Premium
Company Announcements
Armata Gains FDA Fast Track for AP-SA02 Therapy
5M ago
8K
ARMP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >